Escala Medical raises $4.5M Series A for safer pelvic prolapse treatment
Co-financed by the EIC Fund, the raise will support global expansion of Escala’s FDA-approved women’s health solution for pelvic organ prolapse.
Escala Medical has announced the successful completion of a $4.5 million Series A funding round.
The investment was co-financed by the European Innovation Council (EIC) Fund, following a €2.5 million grant awarded to Escala in October 2023 through its Accelerator program. The round also included participation from private investors in the United States and Israel.
With this latest raise, Escala has now secured over $8 million in total funding, further supported by The Trendlines Group, UK-based Consensus Business Group (CBG), and other private investors.
“This funding marks an important milestone as we continue to scale our operations and bring our breakthrough technology to more women worldwide,” stated Dr. Edit Goldberg, CEO of Escala. “We’re proud to have the support of the EIB and our private investors, and we remain committed to advancing the next generation of our Mendit device to improve outcomes and expand access to millions of women worldwide who suffer from organ prolapse.”
Escala specializes in innovative repair solutions for women with Pelvic Organ Prolapse (POP). Its flagship device, Mendit, developed in collaboration with Trendlines, has already been used in over 500 successful procedures.
The company was founded in 2014 by pelvic surgeons Dr. Roger Goldberg and Professor Douglas Scherr, who, as Edit Goldberg explained to CTech, “recognized a significant gap in the treatment of pelvic organ prolapse (POP) for women who are either ineligible for surgery, are unhappy with supportive therapies, or are unwilling to undergo an invasive surgical procedure.”
Goldberg noted that while nearly 50% of women over age 40 experience POP, only 10% undergo surgery due to the risks and recovery.
“The device offers a minimally invasive, office-based alternative to traditional surgery, combining surgical-grade effectiveness with unmatched versatility,” she continued.
“As the first truly minimally invasive, reversible anchor-based system, Mendit opens the door to treatment for the 90% of women who currently go without care.”
According to Goldberg, the POP treatment market exceeds $7 billion globally, with over 8 million women seeking care annually in the U.S. and Europe. Main customers include hospitals, ambulatory surgery centers, and private clinics, with procedures performed by gynecologists, urogynecologists, and urologists.
While competitors include suture passers and other anchor-based systems (such as EnPlace, AnchorSure, and Saffron), all require incisions and operating rooms. Goldberg says Mendit uniquely offers an incision-free, reversible, and office-based repair.
In the U.S., Mendit received FDA clearance in April 2023 and was commercially launched in October 2023. Since then, the device has been approved in 48 hospitals (including several major U.S. health systems) with dozens more in advanced stages of approval.
In Israel, Mendit is approved by the Ministry of Health, and CE mark approval is anticipated in 2026.
Goldberg told CTech the funds from this latest round will be used for commercial expansion in the U.S., as well as market entry in Europe (pending CE approval) and Southeast Asia, following a newly signed distribution agreement with a Singapore-based partner covering the SEA region. The funds will also go toward product enhancement and post-market clinical studies.
"Being selected for the EIC Accelerator and receiving both a grant and equity investment from the EIC Fund is a major vote of confidence in our technology, our team, and our vision,” added Robert D. Auerbach, M.D., Chair of Escala.
Svetoslava Georgieva, Chair of the EIC Fund Board, said the EIC’s support of Escala “marks a significant milestone in their journey to bring much-needed innovation to women's health.”
